Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22225980 | 0.93 | GRM5 (0.41) | GRM5CYP11B2USP30CSNK2A1CSNK2A2 | |
| SCHEMBL22225979 | 0.92 | GRM5 (0.40) | GRM5CYP11B2USP30CSNK2A1CSNK2A2 | |
| SCHEMBL23311868 | 0.84 | GRM5 (0.46) | GRM5CYP11B2USP30CSNK2A1CSNK2A2 | |
| SCHEMBL21597010 | 0.83 | GRM5 (0.47) | GRM5CYP11B2USP30CSNK2A1CSNK2A2 | |
| SCHEMBL29933812 | 0.82 | GRM5 (0.47) | GRM5CYP11B2USP30CSNK2A1CSNK2A2 | |
| SCHEMBL23791581 | 0.82 | GRM5 (0.47) | GRM5CYP11B2USP30CSNK2A1CSNK2A2 | |
| SCHEMBL14349420 | 0.82 | CYP11B2 (0.60) | GRM5CYP11B2EGFROPRK1SLC22A6 | |
| SCHEMBL22226809 | 0.81 | CYP11B2 (0.43) | CYP11B2CSNK2A1CSNK2A2OPRK1USP2 | |
| SCHEMBL21590262 | 0.81 | USP30 (0.38) | GRM5USP30CSNK2A1CSNK2A2EGFR | |
| SCHEMBL23235575 | 0.80 | GRM5 (0.46) | GRM5CYP11B2OPRK1SLC22A6SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577217-B2 | 15-PGDH inhibitor | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2026-03-17 | — | — | US | disclosed |
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | NIPPON SHINYAKU CO., LTD. (JP) | 2025-12-30 | — | — | US | disclosed |
| US-12338240-B2 | Nonmuscle myosin ii inhibitors | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250163056-A1 | NONMUSCLE MYOSIN II INHIBITORS | THE UNIV OF FLORIDA RESEARCH FOUNDATION INC (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4516777-A2 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | Nippon Shinyaku Co., Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| CN-119371371-A | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2025-01-28 | — | — | CN | disclosed |
| CN-115315421-B | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2024-12-03 | — | — | CN | disclosed |
| CN-113226310-B | 15-PGDH inhibitors | 杏林制药株式会社 | 2024-03-19 | — | — | CN | disclosed |
| US-20230391770-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LIMITED (GB) | 2023-12-07 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| EP-1608377-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARM INC (CA) | 2008-10-01 | — | — | EP | disclosed |
| US-20080125423-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2008-05-29 | — | — | US | disclosed |
| US-7250424-B2 | E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide, useful in the treatment bacterial infections. | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-07-31 | — | — | US | disclosed |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-06-29 | — | — | US | disclosed |
| US-20060116394-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2006-06-01 | — | — | US | disclosed |
| US-7049310-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-05-23 | — | — | US | disclosed |
| US-20050250810-A1 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-11-10 | — | — | US | disclosed |
| US-6846819-B1 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-01-25 | — | — | US | disclosed |
| EP-1226138-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-12-29 | — | — | EP | disclosed |
| US-20040147580-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577217-B2 | 15-PGDH inhibitor | PTGDR, ADH1A, ADRA1A | GRM5 992/4885CYP11B2 68/4885USP30 2814/4885 |
| US-20050250810-A1 | FAB I inhibitors | SERPINB1, TFPI, TFPI2 | GRM5 4738/4885CYP11B2 3110/4885USP30 3504/4885 |
| US-20230391770-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, DIMT1, TPMT | GRM5 2992/4885CYP11B2 2308/4885USP30 739/4885 |
| US-20250163056-A1 | NONMUSCLE MYOSIN II INHIBITORS | MYH2, MYO3B, MYO1B | GRM5 523/4885CYP11B2 282/4885USP30 2805/4885 |
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | PDGFRA, PDGFRB, PDGFA | GRM5 399/4885CYP11B2 2874/4885USP30 3978/4885 |
| US-20060116394-A1 | Fab I inhibitors | SERPINB1, TMBIM6, GDI2 | GRM5 4751/4885CYP11B2 4524/4885USP30 3380/4885 |
| US-20080125423-A1 | Fab I Inhibitors | SERPINB1, TFPI, TFPI2 | GRM5 4738/4885CYP11B2 3110/4885USP30 3504/4885 |
| US-20040147580-A1 | Fab I inhibitors | SERPINB1, TMBIM6, GDI1 | GRM5 4767/4885CYP11B2 4503/4885USP30 3321/4885 |
| US-12338240-B2 | Nonmuscle myosin ii inhibitors | MYH2, MYO3B, MYO1B | GRM5 523/4885CYP11B2 282/4885USP30 2805/4885 |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | DBI, SERPINB1, CTSF | GRM5 4628/4885CYP11B2 4671/4885USP30 3876/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | GRM5 486/4885CYP11B2 445/4885USP30 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.